The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma
Abstract
Malignant pleural mesothelioma is a fatal neoplasm that is unresponsive to standard modalities of cancer therapy. We conducted a phase I dose-escalation clinical trial of adenoviral (Ad)-mediated intrapleural herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) gene therapy in patients with mesothelioma as a model for treatment of a localized malignancy. The goals of this phase I trial were to assess the safety, toxicity, and maximally tolerated dose of intrapleural Ad.HSVtk, to examine patient inflammatory response to the viral vector, and to evaluate the efficiency of intratumoral gene transfer. Twenty-one previously untreated patients were enrolled in this single-arm, dose-escalation study with viral doses ranging from 1 × 109 plaque-forming units (pfu) to 1 × 1012 pfu. A replication-incompetent recombinant adenoviral vector containing the HSVtk gene under control of the Rous sarcoma virus (RSV) promoter-enhancer was introduced into the pleural cavity of patients with malignant mesothelioma followed by 2 weeks of systemic therapy with GCV at a dose of 5 mg/kg twice a day. The initial 15 patients underwent thoracoscopic pleural biopsy prior to, and 3 days after, vector delivery. The last six patients underwent only the post-vector instillation biopsy. Dose-limiting toxicity was not reached. Side effects were minimal and included fever, anemia, transient liver enzyme elevations, and bullous skin eruptions, as well as a temporary systemic inflammatory response in those receiving the highest dose. Strong intrapleural and intratumoral immune responses were generated. Using RNA PCR, in situ hybridization, immunohistochemistry, and immunoblotting, HSVtk gene transfer was documented in 11 of 20 evaluable patients in a dose-related fashion. This study demonstrates that intrapleural administration of an adenoviral vector containing the HSVtk gene is well tolerated and results in detectable gene transfer when delivered at high doses. Further development of therapeutic trials for treatment of localized malignancy using this vector is thus warranted. A phase I clinical trial was conducted to establish the safety, side effect profile, maximally tolerated dose, and gene transfer efficiency of an adenoviral vector delivered intrapleurally into patients with a localized malignancy, pleural mesothelioma. A recombinant adenoviral vector containing the herpes simplex virus thymidine kinase gene (HSVtk) under control of the Rous sarcoma virus (RSV) promoter-enhancer was introduced into the pleural cavity of 21 patients with unresectable malignant mesothelioma, followed by 2 weeks of systemic therapy with the antiviral prodrug ganciclovir (GCV). Viral dose ranged from 1 × 109 plaque-forming units (pfu) to 1 × 1012 pfu. Dose-limiting toxicity was not reached. Side effects were minimal. Gene transfer was confirmed in 11 of 20 evaluable patients in a dose-related fashion. This study demonstrates that intrapleural administration of an adenoviral vector containing the HSVtk gene is well tolerated and results in detectable gene transfer when delivered at high doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., & Blaese, R. M. (1992) · Science · doi:10.1126/science.1317968 · Cited by 1,509
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., & Abraham, G. N. (1993) · PubMed · Cited by 1,084
Transfer of Genes to Humans: Early Lessons and Obstacles to Success
Crystal, R. G. (1995) · Science · doi:10.1126/science.270.5235.404 · Cited by 1,000
Crystal, R. G., McElvaney, N. G., Rosenfeld, M. A., Chu, C.-S., Mastrangeli, A., Hay, J. G., Brody, S. L., Jaffe, H. A., Eissa, N. T., & Danel, C. (1994) · Nature Genetics · doi:10.1038/ng0994-42 · Cited by 826
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Knowles, M. R., Hohneker, K. W., Zhou, Z., Olsen, J. C., Noah, T. L., Hu, P.-C., Leigh, M. W., Engelhardt, J. F., Edwards, L. J., Jones, K. R., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331302 · Cited by 566
Self-citationChen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G., & Woo, S. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3054 · Cited by 478
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.
Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M., & Oldfield, E. H. (1993) · PubMed · Cited by 433
Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.
Caruso, M., Panis, Y. H., Gagandeep, S., Houssin, D. P., Salzmann, J. L., & Klatzmann, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.15.7024 · Cited by 370
Antiviral Activity and Mechanism of Action of Ganciclovir
Matthews, T., & Boehme, R. (1988) · Clinical Infectious Diseases · doi:10.1093/clinids/10.supplement_3.s490 · Cited by 364
Cited by
Update on adenovirus and its vectors
Russell, W. C. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2573 · Cited by 596
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Self-citationManagement of Malignant Pleural Effusions
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.ats8-00 · Cited by 498
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.763 · Cited by 496
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Gambhir, S. S., Barrio, J. R., Phelps, M. E., Iyer, M., Namavari, M., Satyamurthy, N., Wu, L., Green, L. A., Bauer, E., MacLaren, D. C., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2333 · Cited by 450
Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320
In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial
Herman, J. R., Adler, H. L., Aguilar-Cordova, E., Rojas-Martinez, A., Woo, S., Timme, T. L., Wheeler, T. M., Thompson, T. C., & Scardino, P. T. (1999) · Human Gene Therapy · doi:10.1089/10430349950018229 · Cited by 301
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
Metadata
- Authors
- Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M., & Kaiser, L. R.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1998-05
- Volume
- 9
- Issue
- 7
- Pages
- 1083-1092
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2086474743
- Cited by
- 341
- References
- 25
- FWCI
- 23.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.